Day One Valuation
| DAWN Stock | USD 13.34 0.28 2.06% |
At this time, the firm appears to be undervalued. Day One Biopharmaceu shows a prevailing Real Value of $19.87 per share. The current price of the firm is $13.34. Our model computes the value of Day One Biopharmaceu from reviewing the firm fundamentals such as Current Valuation of 817.76 M, shares outstanding of 100.85 M, and Profit Margin of (0.83) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Day One's valuation include:
Price Book 2.4728 | Enterprise Value 817.8 M | Enterprise Value Ebitda (7.18) | Price Sales 13.4721 | Enterprise Value Revenue 8.0209 |
Undervalued
Today
Please note that Day One's price fluctuation is not too volatile at this time. Calculation of the real value of Day One Biopharmaceu is based on 3 months time horizon. Increasing Day One's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Day One is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Day Stock. However, Day One's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.34 | Real 19.87 | Target 38.78 | Hype 13.35 | Naive 12.19 |
The intrinsic value of Day One's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Day One's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Day One Biopharmaceuticals helps investors to forecast how Day stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Day One more accurately as focusing exclusively on Day One's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Day One's intrinsic value based on its ongoing forecasts of Day One's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Day One's closest peers.
Day One Cash |
|
Day Valuation Trend
Knowing Day One's actual value is paramount for traders when making sound investment determinations. Using both Day One's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Day Revenue by Product
Day One Total Value Analysis
Day One Biopharmaceuticals is currently anticipated to have valuation of 817.76 M with market capitalization of 1.37 B, debt of 408 K, and cash on hands of 394.86 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Day One fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
817.76 M | 1.37 B | 408 K | 394.86 M |
Day One Asset Utilization
One of the ways to look at asset utilization of Day is to check how much profit was generated for every dollar of assets it reports. Day One Biopharmaceuticals shows a negative utilization of assets of -0.25 percent, losing $0.002543 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Day One Biopharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Day One Ownership Allocation
Day One holds a total of 100.85 Million outstanding shares. The majority of Day One Biopharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Day One Biopharmaceu to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Day One. Please pay attention to any change in the institutional holdings of Day One Biopharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost ten million one hundred sixty-five thousand two hundred seventy-seven invesors are currently shorting Day One expressing very little confidence in its future performance.Day One Profitability Analysis
Net Loss for the year was (188.92 M) with profit before overhead, payroll, taxes, and interest of 0.About Day One Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Day One Biopharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Day One Biopharmaceu based exclusively on its fundamental and basic technical indicators. By analyzing Day One's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Day One's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Day One. We calculate exposure to Day One's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Day One's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -383 K | -402.1 K |
Day One Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 79.8 M |
Day One Current Valuation Indicators
Day One's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Day One's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Day One, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Day One's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Day One's worth.When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.144 | Return On Assets (0.25) | Return On Equity (0.18) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.